Forward Pharma sues Biogen Idec over Tecfidera sales in Germany
Danish biopharmaceutical company Forward Pharma (Nasdaq: FWP) has filed a law suit against US biotech major Biogen Idec (Nasdaq: BIIB) and its European subsidiaries alleging infringement of its German utility model DE 20 2005 022 112 due to Biogen Idec's marketing of Tecfidera (dimethyl fumarate) in Germany.
With this law suit in the Regional Court in Dusseldorf, Forward Pharma does not seek to stop sales of Tecfidera to multiple sclerosis patients, but rather seeks damages for what the company believes are Biogen Idec's unlawful sales of Tecfidera in Germany.
Tecfidera was approved by the European Commission in January 2014. Worldwide sales of the drug as reported by Biogen Idec for the previous four quarters totaled nearly $2.4 billion, including $317 million of ex-US sales. Third quarter Tecfidera sales in Germany represented around 75% of the reported $149 million in ex-US Tecfidera sales, according the Biogen Idec’s latest financial results.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze